Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603 | Zendy

Yasuyuki Kawamoto | Zendy; Satoshi Yuki | Zendy; Kentaro Sawada | Zendy; Michio Nakamura | Zendy; Osamu Muto | Zendy; Susumu Sogabe | Zendy; Yoshiaki Shindo | Zendy; Atsushi Ishiguro | Zendy; Atsushi Satō | Zendy; Yasushi Tsuji | Zendy; Masayoshi Dazai | Zendy; Hiroyuki Okuda | Zendy; Takashi Meguro | Zendy; Kazuaki Harada | Zendy; M Sekiguchi | Zendy; Kazufumi Okada | Zendy; Yoichi M. Ito | Zendy; Yuh Sakata | Zendy; Naoya Sakamoto | Zendy; Yoshito Komatsu | Zendy

Open Access

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603

Author(s) -

Yasuyuki Kawamoto,

Satoshi Yuki,

Kentaro Sawada,

Michio Nakamura,

Osamu Muto,

Susumu Sogabe,

Yoshiaki Shindo,

Atsushi Ishiguro,

Atsushi Satō,

Yasushi Tsuji,

Masayoshi Dazai,

Hiroyuki Okuda,

Takashi Meguro,

Kazuaki Harada,

M Sekiguchi,

Kazufumi Okada,

Yoichi M. Ito,

Yuh Sakata,

Naoya Sakamoto,

Yoshito Komatsu

Publication year - 2022

Publication title -

the oncologist

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.176

H-Index - 164

eISSN - 1549-490X

pISSN - 1083-7159

DOI - 10.1093/oncolo/oyac086

Subject(s) - ramucirumab , medicine , irinotecan , neutropenia , clinical endpoint , leukopenia , febrile neutropenia , combination therapy , adverse effect , progression free survival , gastroenterology , oncology , cancer , chemotherapy , surgery , randomized controlled trial , colorectal cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research